PF4 and p17-70 Peptides Help Fight Myeloma
Author Information
Author(s): Yang Longjiang, Du Juan, Hou Jian, Jiang Hua, Zou Jianfeng
Primary Institution: Department of Hematology, Changzheng Hospital, The Second Military Medical University
Hypothesis
Overexpression of the PF4 gene or p17-70 in myeloma cells would inhibit the growth of myeloma by inhibiting the functions of proangiogenic factors such as FGF2 and VEGF.
Conclusion
PF4 or p17-70 could be valuable in combating multiple myeloma by disrupting tumor angiogenesis.
Supporting Evidence
- PF4 and p17-70 significantly reduced VEGF production in myeloma cells.
- PF4 or p17-70 caused a significant reduction in microvessel densities in myeloma xenografts.
- Kaplan-Meier analysis demonstrated that PF4 and p17-70 significantly extended the overall survival of SCID mice bearing human myeloma xenografts.
Takeaway
Researchers found that two proteins, PF4 and p17-70, can help stop cancer cells from growing by blocking the blood vessels they need to survive.
Methodology
The study involved stably transfecting human myeloma cell lines with the PF4 gene or the sequence encoding its p17-70 peptide and investigating their effects on angiogenesis and tumor growth in vitro and in a SCID-rab myeloma model.
Statistical Information
P-Value
P < 0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website